Rapport Therapeutics, Inc. - Common Stock (RAPP)

This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.

Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.

Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.

Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts by surprise. After years of trading in the shadow of high interest rates and regulatory uncertainty, the industry

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results that are validating extensive research and development efforts across the industry. Investors are demonstrating a renewed appetite for risk,

Rapport Therapeutics beats Q3 earnings estimates, reports strong Phase 2a data for its lead drug candidate RAP-219, and has cash into 2029.

Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.

The company is working on a treatment for a form of epilepsy that tends to be difficult to control.

Rapport Therapeutics' RAP-219 cut seizures significantly in a Phase 2a trial, with strong results and a favorable safety profile driving next steps.

After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.